这项荟萃分析旨在确定非诺多泮对患有或处于急性肾损伤(AKI)高风险并接受手术的患者的有益影响。在进行本荟萃分析时,遵循系统评价和荟萃分析(PRISMA)指南的首选报告项目。两名调查人员搜索了包括PubMed在内的电子数据库,EMBASE,还有Cochrane图书馆,从开始到2023年1月10日,进行相关研究。用于搜索相关文章的关键术语包括\"非诺多泮\",“急性肾损伤”和“手术”。主要结果是新AKI的发生率。次要结局包括血清肌酸相对于基线的变化(mg/dl),ICU住院时间(天),肾脏替代疗法(RRT),和全因死亡率,包括30天之前或30天之前的死亡率。本荟萃分析共纳入10项研究,涉及1484例患者。与对照组相比,非诺多潘组的AKI风险较低[风险比(RR):0.73,95%CI:0.57-0.95]。非诺多帕组的ICU住院时间也较短[平均差(MD):-0.35天,95%置信区间(CI):-0.68,-0.03]。在全因死亡率方面没有显著差异,血清肌酐的变化,和RRT。总之,我们对接受大手术的成年患者使用非诺多泮的研究进行的荟萃分析显示,非诺多泮显著降低了AKI的风险,并缩短了ICU住院时间.然而,对全因死亡率或RRT无显著影响.
This meta-analysis aims to determine the beneficial impacts of
fenoldopam on patients with or at high risk of acute kidney injury (AKI) and undergoing surgery. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed while performing the present meta-analysis. Two investigators searched electronic databases including PubMed, EMBASE, and the Cochrane library, from inception until January 10, 2023, for relevant studies. The key terms used to search for relevant articles included \"
fenoldopam\", \"acute kidney injury\" and \"surgery\". The primary outcome was the incidence of new AKI. Secondary outcomes included change in serum creatine from baseline (mg/dl), length of stay in ICU (days), renal replacement therapy (RRT), and all-cause mortality that included mortality before or at 30 days. A total of 10 studies involving 1484 patients were included in the present meta-analysis. The risk of AKI was lower in the
fenoldopam group compared to the control group [risk ratio (RR): 0.73, 95% CI: 0.57-0.95]. The length of ICU stay was also shorter in the
fenoldopam group [mean difference (MD): -0.35 days, 95% confidence interval (CI): -0.68, -0.03]. No significant differences were reported in terms of all-cause mortality, change in serum creatinine, and RRT. In conclusion, our meta-analysis of studies on the use of fenoldopam in adult patients undergoing major surgery showed that
fenoldopam significantly reduces the risk of AKI and shortens ICU stays. However, there was no significant impact on all-cause mortality or RRT.